The 2024 World Conference on Lung Cancer is happening in San Diego from September 7th to 10th! The WCLC website has already released important abstracts. Below are some key research findings from the OA18 oral presentation session on “Treatment of Pleural Mesothelioma, Thymic Carcinoma, and Undifferentiated Thoracic Tumors”
OA18.03 – Real-World Data: Efficacy and Safety of Lenvatinib in Patients with Previously Treated Thymic Carcinoma
OA18.04 – Phase II Study: Pembrolizumab + Lenvatinib in Second-Line Pleural Mesothelioma Patients (PEMMELA Cohort 2)
OA18.06 – SMARCA4-Deficient Tumors: Characteristics and Outcomes of Patients with Undifferentiated Thoracic Tumors
Stay tuned for more updates from WCLC 2024!
